An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Disease Sites:

Neuroblastoma (Pediatrics), Pediatric Solid Tumors

Staging:

N/A

Age Group:

Both

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

131-MIBG

Principal Investigator(s):

Kitko, Carrie

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

08-06-2012

Trial Type:

Treatment

Protocol ID:

VICCPED1249

National Clinical Trial ID:

NCT01590680

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available